ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly
Por:
Álvarez-Escolá C, Venegas-Moreno EM, García-Arnés JA, Blanco-Carrera C, Marazuela-Azpiroz M, Gálvez-Moreno MÁ, Menéndez-Torre E, Aller-Pardo J, Salinas-Vert I, Resmini E, Torres-Vela EM, Gonzalo-Redondo MÁ, Vílchez-Joya R, de Miguel-Novoa MP, Halperín-Rabinovich I, Páramo-Fernández C, de la Cruz-Sugranyes G, Houchard A, Pico A and ACROSTART Study Group
Publicada:
1 may 2019
Ahead of Print:
14 feb 2019
Resumen:
Objectives: The ACROSTART study was intended to determine the time to achieve normalization of GH and IGF-I levels in responding patients with acromegaly administered different dosage regimens of lanreotide Autogel (Somatuline (R) Autogel (R)).
Methods: From March 2013 to October 2013, clinical data from 57 patients from 17 Spanish hospitals with active acromegaly treated with lanreotide for >= 4 months who achieved hormonal control (GH levels <2.5 ng/ml and/or normalized IGF-I levels in >= 2 measurements) were analyzed. The primary objective was to determine the time from start of lanreotide treatment to hormonal normalization.
Results: Median patient age was 64 years, 21 patients were male, 39 patients had undergone surgery, and 14 patients had received radiotherapy. Median hormonal values at start of lanreotide treatment were: GH, 2.6 ng/ml; IGF-I, 1.6 x ULN. The most common starting dose of lanreotide was 120 mg (29 patients). The main initial regimens were 60 mg/4 weeks (n=13), 90 mg/4 weeks (n=6), 120 mg/4 weeks (n=13), 120 mg/6 weeks (n=6), and 120 mg/8 weeks (n=9). An initial treatment regimen with a long interval (>6 weeks) was administered in 25 patients. Mean duration of lanreotide treatment was 68 months (7-205). Median time to achieve hormonal control was 4.9 months. Injections were managed without healthcare assistance in 13 patients. Median number of visits to endocrinologists until hormonal control was achieved was 3. Fifty-one patients were "satisfied" / "very satisfied" with treatment and 49 patients did not miss any dose.
Conclusions: Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals. (C) 2019 SEEN y SED. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
Álvarez-Escolá C:
Endocrinology and Nutrition Department, Hospital Universitario La Paz, Madrid, Spain
Venegas-Moreno EM:
Endocrinology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
García-Arnés JA:
Endocrinology and Nutrition Service, Hospital Regional Universitario de Málaga, Málaga, Spain
Blanco-Carrera C:
Endocrinology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
Marazuela-Azpiroz M:
Endocrinology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Instituto Princesa, Madrid, Spain
Gálvez-Moreno MÁ:
Endocrinology Service, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain
Menéndez-Torre E:
Endocrinology and Nutrition Department, Hospital Universitario Central de Asturias, Oviedo, Spain
Aller-Pardo J:
Endocrinology Department, Neuroendocrinology Endocrine Oncology Unit, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
Salinas-Vert I:
Endocrinology and Nutrition Department, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
Resmini E:
Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), IIB-Sant Pau, Barcelona, Spain
Universitat Autònoma de Barcelona, Barcelona, Spain
Torres-Vela EM:
Endocrinology and Nutrition, Complejo Hospitalario Universitario, Granada, Spain
Gonzalo-Redondo MÁ:
Endocrinology and Nutrition Department, Fundación Jiménez Díaz, Madrid, Spain
Vílchez-Joya R:
Endocrinology and Nutrition Service, Hospital Universitario Virgen de las Nieves, Granada, Spain
de Miguel-Novoa MP:
Endocrinology Department, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
Halperín-Rabinovich I:
Endocrinology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Páramo-Fernández C:
Endocrinology and Nutrition Department, Complejo Hospitalario Xeral-Cies de Vigo, Vigo, Pontevedra, Spain
de la Cruz-Sugranyes G:
Medical Department, IPSEN PHARMA S.A., L'Hospitalet de Llobregat, Barcelona, Spain
Houchard A:
Statistics Department, IPSEN PHARMA, Boulogne-Billancourt, France
Pico A:
Endocrinology Department, Hospital General Universitario de Alicante-ISABIAL-FISABIO, Alicante, Spain
Open Access
|